



MASSACHUSETTS

Blue Cross Blue Shield of Massachusetts is an independent  
Licensee of the Blue Cross and Blue Shield Association

## Medical Policy

### Amniotic Membrane and Amniotic Fluid

#### Table of Contents

- [Policy: Commercial](#)
- [Coding Information](#)
- [Information Pertaining to All Policies](#)
- [Policy: Medicare](#)
- [Description](#)
- [References](#)
- [Authorization Information](#)
- [Policy History](#)

#### Policy Number: 643

BCBSA Reference Number: 7.01.149 (For Plan internal use only)

NCD/LCD: N/A

#### Related Policies

- Bioengineered Skin and Soft Tissue Substitutes, #[663](#)
- Orthopedic Applications of Stem Cell Therapy, #[254](#)

#### Policy

##### Commercial Members: Managed Care (HMO and POS), PPO, and Indemnity Medicare HMO Blue<sup>SM</sup> and Medicare PPO Blue<sup>SM</sup> Members

Treatment of nonhealing\* diabetic lower-extremity ulcers using the following human amniotic membrane products (Affinity®, AmnioBand® Membrane, Biovance®, EpiCord®, Epifix®, Grafix™) may be considered **MEDICALLY NECESSARY**.

\*Nonhealing of diabetic wounds is defined as less than a 20% decrease in wound area with standard wound care for at least 2 weeks, based on the entry criteria for clinical trials.

Human amniotic membrane grafts with or without suture (eg, Prokera®, AmbioDisk™) may be considered **MEDICALLY NECESSARY** for the treatment of the following ophthalmic indications:

- Neurotrophic keratitis with ocular surface damage and inflammation that does not respond to conservative therapy. Conservative therapy for neurotrophic keratitis may include 5 days of pressure patching, therapeutic contact lens, topical lubricants, and topical antibiotics.
- Corneal ulcers and melts that do not respond to initial conservative therapy. Conservative therapy for corneal ulcers and melts may include 2 days of patching, therapeutic contact lens, and topical antimicrobial agents.
- Corneal perforation when there is active inflammation after corneal transplant requiring adjunctive treatment;
- Bullous keratopathy as a palliative measure in individuals who are not candidates for curative treatment (eg, endothelial or penetrating keratoplasty);
- Partial limbal stem cell deficiency with extensive diseased tissue where selective removal alone is not sufficient;
- Moderate or severe Stevens-Johnson syndrome;

- Persistent epithelial defects that do not respond to conservative therapy. A persistent epithelial defect is one that failed to close completely after 5 days of conservative treatment or has failed to demonstrate a decrease in size after 2 days of conservative treatment. Conservative treatment of a persistent epithelial defect may include 5 days of the following: topical lubricants, topical antibiotics, therapeutic contact lens, or patching.
- Severe dry eye (DEWS 3 or 4)\*\* with ocular surface damage and inflammation that remains symptomatic after Steps 1, 2, and 3 of the dry eye disease management algorithm\*\*\* or
- Moderate or severe acute ocular chemical burn.

Human amniotic membrane grafts with suture or glue may be considered **MEDICALLY NECESSARY** for the treatment of the following ophthalmic indications:

- Corneal perforation when corneal tissue is not immediately available; or
- Pterygium repair when there is insufficient healthy tissue to create a conjunctival autograft.

Human amniotic membrane grafts with or without suture are considered **INVESTIGATIONAL** for all ophthalmic indications not outlined above.

Injection of micronized or particulated human amniotic membrane is considered **INVESTIGATIONAL** for all indications, including but not limited to treatment of osteoarthritis and plantar fasciitis.

Injection of human amniotic fluid is considered **INVESTIGATIONAL** for all indications.

All other human amniotic products (eg, derived from amnion, chorion, amniotic fluid, umbilical cord, or Wharton's jelly) not listed above are considered **INVESTIGATIONAL**.

All other indications not listed above are considered **INVESTIGATIONAL**, including but not limited to treatment of lower-extremity ulcers due to venous insufficiency and repair following Mohs micrographic surgery.

**\*\* Dry eye severity level DEWS 3 to 4**

Discomfort, severity, and frequency - Severe frequent or constant
Visual symptoms - chronic and/or constant, limiting to disabling
Conjunctival Injection - +/- or +/+
Conjunctive Staining - moderate to marked
Corneal Staining - marked central or severe punctate erosions
Corneal/tear signs - Filamentary keratitis, mucus clumping, increase in tear debris
Lid/meibomian glands - Frequent
Tear film breakup time - < 5
Schirmer score (mm/5 min) - < 5

**\*\*\* Tear Film and Ocular Surface Society staged management for dry eye disease**

<b>Step 1:</b>
<ul style="list-style-type: none"> <li>• Education regarding the condition, its management, treatment and prognosis</li> <li>• Modification of local environment</li> <li>• Education regarding potential dietary modifications (including oral essential fatty acid supplementation)</li> <li>• Identification and potential modification/elimination of offending systemic and topical medications</li> <li>• Ocular lubricants of various types (if meibomian gland dysfunction is present, then consider lipid containing supplements)</li> <li>• Lid hygiene and warm compresses of various types</li> </ul>
<b>Step 2:</b>
If above options are inadequate consider: <ul style="list-style-type: none"> <li>• Non-preserved ocular lubricants to minimize preservative-induced toxicity</li> </ul>

- Tea tree oil treatment for Demodex (if present)
- Tear conservation
- Punctal occlusion
- Moisture chamber spectacles/goggles
- Overnight treatments (such as ointment or moisture chamber devices)
- In-office, physical heating and expression of the meibomian glands
- In-office intense pulsed light therapy for meibomian gland dysfunction
- Prescription drugs to manage dry eye disease
- Topical antibiotic or antibiotic/steroid combination applied to the lid margins for anterior blepharitis (if present)
- Topical corticosteroid (limited duration)
- Topical secretagogues
- Topical non-glucocorticoid immunomodulatory drugs (such as cyclosporine)
- Topical LFA-1 antagonist drugs (such as lifitegrast)
- Oral macrolide or tetracycline antibiotics

#### Step 3:

If above options are inadequate consider:

- Oral secretagogues
- Autologous/allogeneic serum eye drops
- Therapeutic contact lens options
- Soft bandage lenses
- Rigid scleral lenses

#### Step 4:

If above options are inadequate consider:

- Topical corticosteroid for longer duration
- Amniotic membrane grafts
- Surgical punctal occlusion
- Other surgical approaches (eg tarsorrhaphy, salivary gland transplantation)

## Prior Authorization Information

### Inpatient

- For services described in this policy, precertification/preauthorization **IS REQUIRED** for all products if the procedure is performed **inpatient**.

### Outpatient

- For services described in this policy, see below for products where prior authorization **might be required** if the procedure is performed **outpatient**.

	Outpatient
<b>Commercial Managed Care (HMO and POS)</b>	Prior authorization is <b>not required</b> .
<b>Commercial PPO and Indemnity</b>	Prior authorization is <b>not required</b> .
<b>Medicare HMO Blue<sup>SM</sup></b>	Prior authorization is <b>not required</b> .
<b>Medicare PPO Blue<sup>SM</sup></b>	Prior authorization is <b>not required</b> .

## CPT Codes / HCPCS Codes / ICD Codes

*Inclusion or exclusion of a code does not constitute or imply member coverage or provider reimbursement. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage as it applies to an individual member.*

*Providers should report all services using the most up-to-date industry-standard procedure, revenue, and diagnosis codes, including modifiers where applicable.*

The following codes are included below for informational purposes only; this is not an all-inclusive list.

The above **medical necessity criteria MUST** be met for the following codes to be covered for Commercial Members: Managed Care (HMO and POS), PPO, Indemnity, Medicare HMO Blue and Medicare PPO Blue:

### HCPCS Codes

HCPCS codes:	Code Description
Q4132	Grafix core and grafixpl core, per square centimeter
Q4133	Grafix prime, grafixpl prime, stravix and stravixpl, per square centimeter
Q4151	Amnioband or guardian, per square centimeter
Q4154	Biovance, per square centimeter
Q4159	Affinity, per square centimeter
Q4168	Amnioband, 1 mg
Q4186	Epifix, per square centimeter
Q4187	Epicord, per sq cm

The following ICD Diagnosis Codes are considered medically necessary when submitted with the HCPCS codes above if **medical necessity criteria** are met:

### ICD-10 Diagnosis Coding

ICD-10-CM-diagnosis codes:	Code Description
E08.621	Diabetes mellitus due to underlying condition with foot ulcer
E08.622	Diabetes mellitus due to underlying condition with other skin ulcer
E09.621	Drug or chemical induced diabetes mellitus with foot ulcer
E09.622	Drug or chemical induced diabetes mellitus with other skin ulcer
E10.621	Type 1 diabetes mellitus with foot ulcer
E10.622	Type 1 diabetes mellitus with other skin ulcer
E11.621	Type 2 diabetes mellitus with foot ulcer
E11.622	Type 2 diabetes mellitus with other skin ulcer
E13.621	Other specified diabetes mellitus with foot ulcer
E13.622	Other specified diabetes mellitus with other skin ulcer

The above **medical necessity criteria MUST** be met for the following codes to be covered for Commercial Members: Managed Care (HMO and POS), PPO, Indemnity, Medicare HMO Blue and Medicare PPO Blue:

### CPT Codes

CPT codes:	Code Description
65779	Placement of amniotic membrane on the ocular surface; single layer, sutured

The following ICD Diagnosis Codes are considered medically necessary when submitted with the HCPCS codes above if **medical necessity criteria** are met:

### ICD-10 Diagnosis Coding

ICD-10-CM-diagnosis codes:	Code Description
----------------------------	------------------

H04.121	Dry eye syndrome of right lacrimal gland
H04.122	Dry eye syndrome of left lacrimal gland
H04.123	Dry eye syndrome of bilateral lacrimal glands
H04.129	Dry eye syndrome of unspecified lacrimal gland
H11.001	Unspecified pterygium of right eye
H11.002	Unspecified pterygium of left eye
H11.003	Unspecified pterygium of eye, bilateral
H11.009	Unspecified pterygium of unspecified eye
H11.011	Amyloid pterygium of right eye
H11.012	Amyloid pterygium of left eye
H11.013	Amyloid pterygium of eye, bilateral
H11.019	Amyloid pterygium of unspecified eye
H11.021	Central pterygium of right eye
H11.022	Central pterygium of left eye
H11.023	Central pterygium of eye, bilateral
H11.029	Central pterygium of unspecified eye
H11.031	Double pterygium of right eye
H11.032	Double pterygium of left eye
H11.033	Double pterygium of eye, bilateral
H11.039	Double pterygium of unspecified eye
H11.041	Peripheral pterygium, stationary, right eye
H11.042	Peripheral pterygium, stationary, left eye
H11.043	Peripheral pterygium, stationary, bilateral
H11.049	Peripheral pterygium, stationary, unspecified eye
H11.051	Peripheral pterygium, progressive, right eye
H11.052	Peripheral pterygium, progressive, left eye
H11.053	Peripheral pterygium, progressive, bilateral
H11.059	Peripheral pterygium, progressive, unspecified eye
H11.061	Recurrent pterygium of right eye
H11.062	Recurrent pterygium of left eye
H11.063	Recurrent pterygium of eye, bilateral
H11.069	Recurrent pterygium of unspecified eye
H16.001	Unspecified corneal ulcer, right eye
H16.002	Unspecified corneal ulcer, left eye
H16.003	Unspecified corneal ulcer, bilateral
H16.009	Unspecified corneal ulcer, unspecified eye
H16.011	Central corneal ulcer, right eye
H16.012	Central corneal ulcer, left eye
H16.013	Central corneal ulcer, bilateral
H16.019	Central corneal ulcer, unspecified eye
H16.021	Ring corneal ulcer, right eye
H16.022	Ring corneal ulcer, left eye
H16.023	Ring corneal ulcer, bilateral
H16.029	Ring corneal ulcer, unspecified eye
H16.031	Corneal ulcer with hypopyon, right eye
H16.032	Corneal ulcer with hypopyon, left eye
H16.033	Corneal ulcer with hypopyon, bilateral
H16.039	Corneal ulcer with hypopyon, unspecified eye
H16.041	Marginal corneal ulcer, right eye
H16.042	Marginal corneal ulcer, left eye
H16.043	Marginal corneal ulcer, bilateral
H16.049	Marginal corneal ulcer, unspecified eye
H16.051	Mooren's corneal ulcer, right eye

H16.052	Mooren's corneal ulcer, left eye
H16.053	Mooren's corneal ulcer, bilateral
H16.059	Mooren's corneal ulcer, unspecified eye
H16.061	Mycotic corneal ulcer, right eye
H16.062	Mycotic corneal ulcer, left eye
H16.063	Mycotic corneal ulcer, bilateral
H16.069	Mycotic corneal ulcer, unspecified eye
H16.071	Perforated corneal ulcer, right eye
H16.072	Perforated corneal ulcer, left eye
H16.073	Perforated corneal ulcer, bilateral
H16.079	Perforated corneal ulcer, unspecified eye
H16.231	Neurotrophic keratoconjunctivitis, right eye
H16.232	Neurotrophic keratoconjunctivitis, left eye
H16.233	Neurotrophic keratoconjunctivitis, bilateral
H16.239	Neurotrophic keratoconjunctivitis, unspecified eye
H18.10	Bullous keratopathy, unspecified eye
H18.12	Bullous keratopathy, left eye
H18.13	Bullous keratopathy, bilateral
H18.831	Recurrent erosion of cornea, right eye
H18.832	Recurrent erosion of cornea, left eye
H18.833	Recurrent erosion of cornea, bilateral
H18.839	Recurrent erosion of cornea, unspecified eye
L51.1	Stevens-Johnson syndrome
T26.50XA	Corrosion of unspecified eyelid and periocular area, initial encounter
T26.50XD	Corrosion of unspecified eyelid and periocular area, subsequent encounter
T26.50XS	Corrosion of unspecified eyelid and periocular area, sequela
T26.51XA	Corrosion of right eyelid and periocular area, initial encounter
T26.51XD	Corrosion of right eyelid and periocular area, subsequent encounter
T26.51XS	Corrosion of right eyelid and periocular area, sequela
T26.52XA	Corrosion of left eyelid and periocular area, initial encounter
T26.52XD	Corrosion of left eyelid and periocular area, subsequent encounter
T26.52XS	Corrosion of left eyelid and periocular area, sequela
T26.60XA	Corrosion of cornea and conjunctival sac, unspecified eye, initial encounter
T26.60XD	Corrosion of cornea and conjunctival sac, unspecified eye, subsequent encounter
T26.60XA	Corrosion of cornea and conjunctival sac, unspecified eye, sequela
T26.61XA	Corrosion of cornea and conjunctival sac, right eye, initial encounter
T26.61XD	Corrosion of cornea and conjunctival sac, right eye, subsequent encounter
T26.61XS	Corrosion of cornea and conjunctival sac, right eye, sequela
T26.62XA	Corrosion of cornea and conjunctival sac, left eye, initial encounter
T26.62XD	Corrosion of cornea and conjunctival sac, left eye, subsequent encounter
T26.62XS	Corrosion of cornea and conjunctival sac, left eye, sequela
T26.70XA	Corrosion with resulting rupture and destruction of unspecified eyeball, initial encounter
T26.70XD	Corrosion with resulting rupture and destruction of unspecified eyeball, subsequent encounter
T26.70XS	Corrosion with resulting rupture and destruction of unspecified eyeball, sequela
T26.71XA	Corrosion with resulting rupture and destruction of right eyeball, initial encounter
T26.71XD	Corrosion with resulting rupture and destruction of right eyeball, subsequent encounter
T26.71XS	Corrosion with resulting rupture and destruction of right eyeball, sequela
T26.72XA	Corrosion with resulting rupture and destruction of left eyeball, initial encounter
T26.72XD	Corrosion with resulting rupture and destruction of left eyeball, subsequent encounter
T26.72XS	Corrosion with resulting rupture and destruction of left eyeball, sequela
T26.80XA	Corrosions of other specified parts of unspecified eye and adnexa, initial encounter
T26.80XD	Corrosions of other specified parts of unspecified eye and adnexa, subsequent encounter

T26.80XS	Corrosions of other specified parts of unspecified eye and adnexa, sequela
T26.81XA	Corrosions of other specified parts of right eye and adnexa, initial encounter
T26.81XD	Corrosions of other specified parts of right eye and adnexa, subsequent encounter
T26.81XS	Corrosions of other specified parts of right eye and adnexa, sequela
T26.82XA	Corrosions of other specified parts of left eye and adnexa, initial encounter
T26.82XD	Corrosions of other specified parts of left eye and adnexa, subsequent encounter
T26.82XS	Corrosions of other specified parts of left eye and adnexa, sequela
T26.90XA	Corrosion of unspecified eye and adnexa, part unspecified, initial encounter
T26.90XD	Corrosion of unspecified eye and adnexa, part unspecified, subsequent encounter
T26.90XS	Corrosion of unspecified eye and adnexa, part unspecified, sequela
T26.91XA	Corrosion of right eye and adnexa, part unspecified, initial encounter
T26.91XD	Corrosion of right eye and adnexa, part unspecified, subsequent encounter
T26.91XS	Corrosion of right eye and adnexa, part unspecified, sequela
T26.92XA	Corrosion of left eye and adnexa, part unspecified, initial encounter
T26.92XD	Corrosion of left eye and adnexa, part unspecified, subsequent encounter
T26.92XS	Corrosion of left eye and adnexa, part unspecified, sequela

The above **medical necessity criteria MUST** be met for the following codes to be covered for Commercial Members: Managed Care (HMO and POS), PPO, Indemnity, Medicare HMO Blue and Medicare PPO Blue:

### CPT Codes

CPT codes:	Code Description
65778	Placement of amniotic membrane on the ocular surface; without sutures

The following ICD Diagnosis Codes are considered medically necessary when submitted with the HCPCS codes above if **medical necessity criteria** are met:

### ICD-10 Diagnosis Coding

ICD-10-CM-diagnosis codes:	Code Description
H04.121	Dry eye syndrome of right lacrimal gland
H04.122	Dry eye syndrome of left lacrimal gland
H04.123	Dry eye syndrome of bilateral lacrimal glands
H04.129	Dry eye syndrome of unspecified lacrimal gland
H16.001	Unspecified corneal ulcer, right eye
H16.002	Unspecified corneal ulcer, left eye
H16.003	Unspecified corneal ulcer, bilateral
H16.009	Unspecified corneal ulcer, unspecified eye
H16.011	Central corneal ulcer, right eye
H16.012	Central corneal ulcer, left eye
H16.013	Central corneal ulcer, bilateral
H16.019	Central corneal ulcer, unspecified eye
H16.021	Ring corneal ulcer, right eye
H16.022	Ring corneal ulcer, left eye
H16.023	Ring corneal ulcer, bilateral
H16.029	Ring corneal ulcer, unspecified eye
H16.031	Corneal ulcer with hypopyon, right eye
H16.032	Corneal ulcer with hypopyon, left eye
H16.033	Corneal ulcer with hypopyon, bilateral
H16.039	Corneal ulcer with hypopyon, unspecified eye

H16.041	Marginal corneal ulcer, right eye
H16.042	Marginal corneal ulcer, left eye
H16.043	Marginal corneal ulcer, bilateral
H16.049	Marginal corneal ulcer, unspecified eye
H16.051	Mooren's corneal ulcer, right eye
H16.052	Mooren's corneal ulcer, left eye
H16.053	Mooren's corneal ulcer, bilateral
H16.059	Mooren's corneal ulcer, unspecified eye
H16.061	Mycotic corneal ulcer, right eye
H16.062	Mycotic corneal ulcer, left eye
H16.063	Mycotic corneal ulcer, bilateral
H16.069	Mycotic corneal ulcer, unspecified eye
H16.231	Neurotrophic keratoconjunctivitis, right eye
H16.232	Neurotrophic keratoconjunctivitis, left eye
H16.233	Neurotrophic keratoconjunctivitis, bilateral
H16.239	Neurotrophic keratoconjunctivitis, unspecified eye
H18.10	Bullous keratopathy, unspecified eye
H18.12	Bullous keratopathy, left eye
H18.13	Bullous keratopathy, bilateral
H18.831	Recurrent erosion of cornea, right eye
H18.832	Recurrent erosion of cornea, left eye
H18.833	Recurrent erosion of cornea, bilateral
H18.839	Recurrent erosion of cornea, unspecified eye
L51.1	Stevens-Johnson syndrome
T26.50XA	Corrosion of unspecified eyelid and periocular area, initial encounter
T26.50XD	Corrosion of unspecified eyelid and periocular area, subsequent encounter
T26.50XS	Corrosion of unspecified eyelid and periocular area, sequela
T26.51XA	Corrosion of right eyelid and periocular area, initial encounter
T26.51XD	Corrosion of right eyelid and periocular area, subsequent encounter
T26.51XS	Corrosion of right eyelid and periocular area, sequela
T26.52XA	Corrosion of left eyelid and periocular area, initial encounter
T26.52XD	Corrosion of left eyelid and periocular area, subsequent encounter
T26.52XS	Corrosion of left eyelid and periocular area, sequela
T26.60XA	Corrosion of cornea and conjunctival sac, unspecified eye, initial encounter
T26.60XD	Corrosion of cornea and conjunctival sac, unspecified eye, subsequent encounter
T26.60XA	Corrosion of cornea and conjunctival sac, unspecified eye, sequela
T26.61XA	Corrosion of cornea and conjunctival sac, right eye, initial encounter
T26.61XD	Corrosion of cornea and conjunctival sac, right eye, subsequent encounter
T26.61XS	Corrosion of cornea and conjunctival sac, right eye, sequela
T26.62XA	Corrosion of cornea and conjunctival sac, left eye, initial encounter
T26.62XD	Corrosion of cornea and conjunctival sac, left eye, subsequent encounter
T26.62XS	Corrosion of cornea and conjunctival sac, left eye, sequela
T26.70XA	Corrosion with resulting rupture and destruction of unspecified eyeball, initial encounter
T26.70XD	Corrosion with resulting rupture and destruction of unspecified eyeball, subsequent encounter
T26.70XS	Corrosion with resulting rupture and destruction of unspecified eyeball, sequela
T26.71XA	Corrosion with resulting rupture and destruction of right eyeball, initial encounter
T26.71XD	Corrosion with resulting rupture and destruction of right eyeball, subsequent encounter
T26.71XS	Corrosion with resulting rupture and destruction of right eyeball, sequela
T26.72XA	Corrosion with resulting rupture and destruction of left eyeball, initial encounter
T26.72XD	Corrosion with resulting rupture and destruction of left eyeball, subsequent encounter
T26.72XS	Corrosion with resulting rupture and destruction of left eyeball, sequela
T26.80XA	Corrosions of other specified parts of unspecified eye and adnexa, initial encounter



T26.80XD	Corrosions of other specified parts of unspecified eye and adnexa, subsequent encounter
T26.80XS	Corrosions of other specified parts of unspecified eye and adnexa, sequela
T26.81XA	Corrosions of other specified parts of right eye and adnexa, initial encounter
T26.81XD	Corrosions of other specified parts of right eye and adnexa, subsequent encounter
T26.81XS	Corrosions of other specified parts of right eye and adnexa, sequela
T26.82XA	Corrosions of other specified parts of left eye and adnexa, initial encounter
T26.82XD	Corrosions of other specified parts of left eye and adnexa, subsequent encounter
T26.82XS	Corrosions of other specified parts of left eye and adnexa, sequela
T26.90XA	Corrosion of unspecified eye and adnexa, part unspecified, initial encounter
T26.90XD	Corrosion of unspecified eye and adnexa, part unspecified, subsequent encounter
T26.90XS	Corrosion of unspecified eye and adnexa, part unspecified, sequela
T26.91XA	Corrosion of right eye and adnexa, part unspecified, initial encounter
T26.91XD	Corrosion of right eye and adnexa, part unspecified, subsequent encounter
T26.91XS	Corrosion of right eye and adnexa, part unspecified, sequela
T26.92XA	Corrosion of left eye and adnexa, part unspecified, initial encounter
T26.92XD	Corrosion of left eye and adnexa, part unspecified, subsequent encounter
T26.92XS	Corrosion of left eye and adnexa, part unspecified, sequela

**The following HCPCS codes are considered investigational for Commercial Members: Managed Care (HMO and POS), PPO, Indemnity, Medicare HMO Blue and Medicare PPO Blue:**

### HCPCS Codes

<b>HCPCS codes:</b>	<b>Code Description</b>
A2001	Innovamatrix ac, per square centimeter
A2013	Innovamatrix fs, per square centimeter
Q4137	Amnioexcel, amnioexcel plus or biodexcel, per square centimeter
Q4138	Biodfence dryflex, per square centimeter
Q4139	AmnioMatrix or BioDMatrix, injectable, 1 cc
Q4140	Biodfence, per square centimeter
Q4145	EpiFix, injectable, 1 mg
Q4148	Neox cord 1k, neox cord rt, or clarix cord 1k, per square centimeter
Q4150	Allowrap ds or dry, per square centimeter
Q4153	Dermavest and plurivest, per square centimeter
Q4155	NeoxFlo or ClarixFlo, 1 mg
Q4156	Neox 100 or clarix 100, per square centimeter
Q4157	Revitalon, per sq cm
Q4158	Kerecis omega3, per square centimeter
Q4160	Nushield, per square centimeter
Q4162	Woundex flow, bioskin flow, 0.5 cc
Q4163	Woundex, bioskin, per square centimeter
Q4169	Artacent wound, per square centimeter
Q4170	Cygnus, per square centimeter
Q4171	Interfyl, 1 mg
Q4173	Palingen or palingen xplus, per square centimeter
Q4174	Palingen or promatrix, 0.36 mg per 0.25 cc
Q4176	Neopatch, per square centimeter
Q4177	Floweramnioflo, 0.1 cc
Q4178	Floweramniopatch, per square centimeter

Q4179	Flowerderm, per square centimeter
Q4180	Revita, per square centimeter
Q4181	Amnio Wound, per sq cm
Q4183	Surgigraft, per square centimeter
Q4184	Cellesta or cellesta duo, per square centimeter
Q4185	Cellesta flowable amnion (25 mg per cc); per 0.5 cc
Q4188	Amnioarmor, per square centimeter
Q4189	Artacent ac, 1 mg
Q4190	Artacent ac, per square centimeter
Q4191	Restorigin, per square centimeter
Q4192	Restorigin, 1 cc
Q4194	Novachor, per square centimeter
Q4198	Genesis amniotic membrane, per square centimeter
Q4199	Cygnus matrix, per square centimeter
Q4201	Matrion, per square centimeter
Q4204	Xwrap, per square centimeter
Q4205	Membrane graft or membrane wrap, per square centimeter
Q4206	Fluid flow or fluid GF, 1 cc
Q4208	Novafix, per square centimeter
Q4209	Surgraft, per square centimeter
Q4210	Axolotl graft or axolotl dualgraft, per square centimeter
Q4211	Amnion bio or Axobiomembrane, per square centimeter
Q4212	Allogen, per cc
Q4213	Ascent, 0.5 mg
Q4214	Cellesta cord, per square centimeter
Q4215	Axolotl ambient or axolotl cryo, 0.1 mg
Q4216	Artacent cord, per square centimeter
Q4217	Woundfix, BioWound, Woundfix Plus, BioWound Plus, Woundfix Xplus or BioWound Xplus, per square centimeter
Q4218	Surgicord, per square centimeter
Q4219	Surgigraft-dual, per square centimeter
Q4221	Amniowrap2, per square centimeter
Q4224	Human health factor 10 amniotic patch (hhf10-p), per square centimeter
Q4225	Amniobind or dermabind tl, per square centimeter
Q4227	Amniocore, per square centimeter
Q4229	Cogenex amniotic membrane, per square centimeter.
Q4230	Cogenex flowable amnion, per 0.5 cc
Q4231	Corplex P, per cc
Q4232	Corplex, per square centimeter
Q4233	Surfactor or Nudyn, per 0.5 cc."
Q4234	Xcellerate, per square centimeter
Q4235	Amniorepair or altipty, per square centimeter
Q4236	Carepatch, per square centimeter
Q4237	Cryo-cord, per square centimeter
Q4238	Derm-maxx, per square centimeter
Q4239	Amnio-maxx or Amnio-maxx lite, per square centimeter
Q4240	Corecyte, for topical use only, per 0.5 cc
Q4241	Polycyte, for topical use only, per 0.5 cc
Q4242	Amniocyte plus, per 0.5 cc

Q4245	Amniotext, per cc
Q4246	Coretext or Protex, per cc
Q4247	Amniotext patch, per square centimeter
Q4248	Dermacyte Amniotic Membrane Allograft, per square centimeter
Q4249	Amniply, for topical use only, per square centimeter
Q4250	Amnioamp-mp, per square centimeter
Q4251	Vim, per square centimeter
Q4252	Vendaje, per square centimeter
Q4253	Zenith amniotic membrane, per square centimeter
Q4254	Novafix dl, per square centimeter
Q4255	Reguard, for topical use only, per square centimeter
Q4256	Mlg-complete, per square centimeter
Q4257	Relese, per square centimeter
Q4258	Enverse, per square centimeter
Q4259	Celera dual layer or celera dual membrane, per square centimeter
Q4260	Signature apatch, per square centimeter
Q4261	Tag, per square centimeter
Q4262	Dual layer impax membrane, per square centimeter
Q4263	Surgraft tl, per square centimeter
Q4264	Cocoon membrane, per square centimeter
Q4265	Neostim tl, per square centimeter
Q4266	Neostim membrane, per square centimeter
Q4267	Neostim dl, per square centimeter
Q4268	Surgraft ft, per square centimeter
Q4269	Surgraft xt, per square centimeter
Q4270	Complete sl, per square centimeter
Q4271	Complete ft, per square centimeter
Q4272	Esano a, per square centimeter
Q4273	Esano aaa, per square centimeter
Q4274	Esano ac, per square centimeter
Q4275	Esano aca, per square centimeter
Q4276	Orion, per square centimeter
Q4277	Woundplus membrane or e-graft, per square centimeter
Q4278	Epieffect, per square centimeter
Q4279	Vendaje ac, per square centimeter
Q4280	Xcell amnio matrix, per square centimeter
Q4281	Barrera sl or barrera dl, per square centimeter
Q4282	Cygnus dual, per square centimeter
Q4283	Biovance tri-layer or biovance 3l, per square centimeter
Q4284	Dermabind sl, per square centimeter
Q4285	Nudyn dl or nudyn dl mesh, per square centimeter
Q4286	Nudyn sl or nudyn slw, per square centimeter
Q4287	Dermabind dl, per square centimeter
Q4288	Dermabind ch, per square centimeter
Q4289	Revoshield + amniotic barrier, per square centimeter
Q4290	Membrane wrap-hydro, per square centimeter
Q4291	Lamellas xt, per square centimeter
Q4292	Lamellas, per square centimeter
Q4293	Acesso dl, per square centimeter
Q4294	Amnio quad-core, per square centimeter
Q4295	Amnio tri-core amniotic, per square centimeter

Q4296	Rebound matrix, per square centimeter
Q4297	Emerge matrix, per square centimeter
Q4298	Amniocore pro, per square centimeter
Q4299	Amnicore pro+, per square centimeter
Q4300	Acesso tl, per square centimeter
Q4301	Activate matrix, per square centimeter
Q4302	Complete aca, per square centimeter
Q4303	Complete aa, per square centimeter
Q4304	Grafix plus, per square centimeter
Q4305	American amnion ac tri-layer, per square centimeter
Q4306	American amnion ac, per square centimeter
Q4307	American amnion, per square centimeter
Q4308	Sanopellis, per square centimeter
Q4309	Via matrix, per square centimeter
Q4310	Procenta, per 100 mg

## Description

### Human Amniotic Membrane

Human amniotic membrane (HAM) consists of 2 conjoined layers, the amnion, and chorion, and forms the innermost lining of the amniotic sac or placenta. When prepared for use as an allograft, the membrane is harvested immediately after birth, cleaned, sterilized, and either cryopreserved or dehydrated. Many products available using amnion, chorion, amniotic fluid, and umbilical cord are being studied for the treatment of a variety of conditions, including chronic full-thickness diabetic lower-extremity ulcers, venous ulcers, knee osteoarthritis, plantar fasciitis, and ophthalmic conditions. The products are formulated either as patches, which can be applied as wound covers, or as suspensions or particulates, or connective tissue extractions, which can be injected or applied topically.

Fresh amniotic membrane contains collagen, fibronectin, and hyaluronic acid, along with a combination of growth factors, cytokines, and anti-inflammatory proteins such as interleukin-1 receptor antagonist.<sup>1</sup> There is evidence that the tissue has anti-inflammatory, antifibroblastic, and antimicrobial properties. HAM is considered nonimmunogenic and has not been observed to cause a substantial immune response. It is believed that these properties are retained in cryopreserved HAM and HAM products, resulting in a readily available tissue with regenerative potential. In support, 1 HAM product has been shown to elute growth factors into saline and stimulate the migration of mesenchymal stem cells, both in vitro and in vivo.<sup>2</sup>

Use of a HAM graft, which is fixated by sutures, is an established treatment for disorders of the corneal surface, including neurotrophic keratitis, corneal ulcers and melts, following pterygium repair, Stevens-Johnson syndrome, and persistent epithelial defects. Amniotic membrane products that are inserted like a contact lens have more recently been investigated for the treatment of corneal and ocular surface disorders. Amniotic membrane patches are also being evaluated for the treatment of various other conditions, including skin wounds, burns, leg ulcers, and prevention of tissue adhesion in surgical procedures.<sup>1</sup> Additional indications studied in preclinical models include tendonitis, tendon repair, and nerve repair. The availability of HAM opens the possibility of regenerative medicine for an array of conditions.

### Amniotic Fluid

Amniotic fluid surrounds the fetus during pregnancy and provides protection and nourishment. In the second half of gestation, most of the fluid is a result of micturition and secretion from the respiratory tract and gastrointestinal tract of the fetus, along with urea.<sup>1</sup> The fluid contains proteins, carbohydrates, peptides, fats, amino acids, enzymes, hormones, pigments, and fetal cells. Use of human and bovine amniotic fluid for orthopedic conditions was first reported in 1927.<sup>3</sup> Amniotic fluid has been compared with synovial fluid, containing hyaluronan, lubricant, cholesterol, and cytokines. Injection of amniotic fluid or

amniotic fluid-derived cells is currently being evaluated for the treatment of osteoarthritis and plantar fasciitis.

Amniotic membrane and amniotic fluid are also being investigated as sources of pluripotent stem cells.<sup>1</sup> Pluripotent stem cells can be cultured and are capable of differentiation toward any cell type. The use of stem cells in orthopedic applications is addressed in policy #254.

## Summary

Several commercially available forms of human amniotic membrane (HAM) and amniotic fluid can be administered by patches, topical application, or injection. Amniotic membrane and amniotic fluid are being evaluated for the treatment of a variety of conditions, including chronic full-thickness diabetic lower-extremity ulcers, venous ulcers, knee osteoarthritis, plantar fasciitis, and ophthalmic conditions.

### Summary of Evidence

#### Diabetic Lower-Extremity Ulcers

For individuals who have non-healing diabetic lower-extremity ulcers who receive a patch or flowable formulation of HAM or placental membrane (ie, Affinity, AmnioBand Membrane, AmnioExcel, Biovance, EpiCord, EpiFix, Grafix), the evidence includes randomized controlled trials (RCTs). Relevant outcomes are symptoms, morbid events, functional outcomes, and quality of life. The RCTs evaluating amniotic and placental membrane products for the treatment of non-healing (<20% healing with  $\geq 2$  weeks of standard care) diabetic lower-extremity ulcers have compared HAM with standard care or with an established advanced wound care product. These trials used wound closure as the primary outcome measure, and some used power analysis, blinded assessment of wound healing, and intention-to-treat analysis. For the HAM products that have been sufficiently evaluated (ie, Affinity, AmnioBand Membrane, Biovance, EpiCord, EpiFix, Grafix), results have shown improved outcomes compared with standard care, and outcomes that are at least as good as an established advanced wound care product. Improved health outcomes in the RCTs are supported by multicenter registries. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

#### Lower-Extremity Ulcers due to Venous Insufficiency

For individuals who have lower-extremity ulcers due to venous insufficiency who receive a patch or flowable formulation of HAM, the evidence includes 2 RCTs. Relevant outcomes are symptoms, morbid events, functional outcomes, and quality of life. The published evidence on HAM for the treatment of venous leg ulcers includes 2 multicenter RCTs with EpiFix. One RCT reported a larger percent wound closure at 4 weeks, but the percentage of patients with complete wound closure at 4 weeks did not differ between EpiFix and the standard of care. A second RCT evaluated complete wound closure at 12 weeks after weekly application of EpiFix or standard dressings with compression, but interpretation is limited by methodologic concerns. Two additional studies with other HAM products have been completed but not published, raising further questions about the efficacy of HAM for venous insufficiency ulcers. Therefore, corroboration with well-designed and well-conducted RCTs evaluating wound healing is needed to demonstrate efficacy for this indication. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

#### Osteoarthritis

For individuals who have knee osteoarthritis who receive an injection of suspension or particulate formulation of HAM or amniotic fluid, the evidence includes a feasibility study. Relevant outcomes are symptoms, functional outcomes, quality of life, and treatment-related morbidity. The pilot study assessed the feasibility of a larger RCT evaluating HAM injection. Additional trials, which will have a larger sample size and longer follow-up, are needed to permit conclusions on the effect of this treatment. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

#### Plantar Fasciitis

The evidence on injection of amniotic membrane for the treatment of plantar fasciitis includes preliminary studies and a larger (N =145) patient-blinded comparison of micronized injectable-HAM and placebo control. Injection of micronized amniotic membrane resulted in greater improvements in the visual analog score for pain and the Foot Functional Index compared to placebo controls. The primary limitation of the

study is that this is an interim report with 12-month results pending. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

### **Ophthalmic Conditions**

Sutured HAM transplant has been used for many years for the treatment of ophthalmic conditions. Many of these conditions are rare, leading to difficulty in conducting RCTs. The rarity, severity, and variability of the ophthalmic condition was taken into consideration in evaluating the evidence.

### **Neurotrophic Keratitis with Ocular Surface Damage and Inflammation That Does Not Respond to Conservative Therapy**

For individuals who have neurotrophic keratitis with ocular surface damage and inflammation that does not respond to conservative therapy who receive HAM, the evidence includes an RCT. Relevant outcomes are symptoms, morbid events, functional outcomes, and quality of life. An RCT of 30 patients showed no benefit of sutured HAM graft compared to tarsorrhaphy or bandage contact lens. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

### **Corneal Ulcers and Melts That Do Not Respond to Initial Medical Therapy**

For individuals who have corneal ulcers and melts, that do not respond to initial medical therapy who receive HAM, the evidence includes a systematic review of primarily case series and a non-randomized comparative study. Relevant outcomes are symptoms, morbid events, functional outcomes, and quality of life. Corneal ulcers and melts are uncommon and variable and additional RCTs are not expected. The systematic review showed healing in 97% of patients with an improvement of vision in 53% of eyes. One retrospective comparative study with 22 patients found more rapid and complete epithelialization and more patients with a clinically significant improvement in visual acuity following early treatment with self-retained amniotic membrane when compared to historical controls. Corneal ulcers and melts are uncommon and variable and RCTs are not expected. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

### **Corneal Perforation When There is Active Inflammation After Corneal Transplant Requiring Adjunctive Treatment**

For individuals who have corneal perforation when there is active inflammation after corneal transplant requiring adjunctive treatment who receive HAM, the evidence is limited. Relevant outcomes are symptoms, morbid events, functional outcomes, and quality of life. No comparative evidence was identified for this indication. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

### **Bullous Keratopathy as a Palliative Measure in Individuals Who are Not Candidates for a Curative Treatment (eg, Endothelial or Penetrating Keratoplasty)**

For individuals who have bullous keratopathy and who are not candidates for curative treatment (eg, endothelial or penetrating keratoplasty) who receive HAM, the evidence includes an RCT. Relevant outcomes are symptoms, morbid events, functional outcomes, and quality of life. An RCT found no advantage of sutured HAM over the simpler stromal puncture procedure for the treatment of pain from bullous keratopathy. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

### **Partial Limbal Stem Cell Deficiency with Extensive Diseased Tissue Where Selective Removal Alone is Not Sufficient**

For individuals who have partial limbal stem cell deficiency with extensive diseased tissue where selective removal alone is not sufficient who receive HAM, the evidence is limited. Relevant outcomes are symptoms, morbid events, functional outcomes, and quality of life. No comparative trials were identified on HAM for limbal stem cell deficiency. Improvement in visual acuity has been reported for some patients who have received HAM in conjunction with removal of the diseased limbus. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

### **Moderate or Severe Stevens-Johnson Syndrome**

For individuals who have moderate or severe Stevens-Johnson syndrome who receive HAM, the evidence includes an RCT. Relevant outcomes are symptoms, morbid events, functional outcomes, and quality of life. The evidence on HAM for the treatment of Stevens-Johnson syndrome (includes 1 RCT with 25 patients [50 eyes]) found improved symptoms and function with HAM compared to medical therapy alone. Large RCTs are unlikely due to the severity and rarity of the disease. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

#### **Persistent Epithelial Defects and Ulceration That Do Not Respond to Conservative Therapy**

For individuals who have persistent epithelial defects that do not respond to conservative therapy who receive HAM, the evidence is limited. Relevant outcomes are symptoms, morbid events, functional outcomes, and quality of life. No comparative trials were identified on persistent epithelial defects and ulceration. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

#### **Severe Dry Eye with Ocular Surface Damage and Inflammation That Does Not Respond to Conservative Therapy**

For individuals who have severe dry eye with ocular surface damage and inflammation that does not respond to conservative therapy, who receive HAM, the evidence includes an RCT and a large case series. Relevant outcomes are symptoms, morbid events, functional outcomes, and quality of life. The evidence on HAM for severe dry eye with ocular surface damage and inflammation includes an RCT with 20 patients and a retrospective series of 84 patients (97 eyes). Placement of self-retained HAM for 2 to 11 days reduced symptoms and restored a smooth corneal surface and corneal nerve density for as long as 3 months. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

#### **Moderate or Severe Acute Ocular Chemical Burns**

For individuals who have moderate or severe acute ocular chemical burn who receive HAM, the evidence includes 3 RCTs. Relevant outcomes are symptoms, morbid events, functional outcomes, and quality of life. Evidence includes a total of 197 patients with acute ocular chemical burns who were treated with HAM transplantation plus medical therapy or medical therapy alone. Two of the 3 RCTs did not show a faster rate of epithelial healing, and there was no significant benefit for other outcomes. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

#### **Corneal Perforation When Corneal Tissue is Not Immediately Available**

For individuals who have corneal perforation when corneal tissue is not immediately available who receive sutured HAM, the evidence is limited. Relevant outcomes are symptoms, morbid events, functional outcomes, and quality of life. The standard treatment for corneal perforation is corneal transplantation, however, HAM may provide temporary coverage of the severe defect when corneal tissue is not immediately available. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

#### **Pterygium Repair When There is Insufficient Healthy Tissue to Create a Conjunctival Autograft**

For individuals who have pterygium repair when there is insufficient healthy tissue to create a conjunctival autograft who receive HAM, the evidence includes RCTs and systematic reviews of RCTs. Relevant outcomes are symptoms, morbid events, functional outcomes, and quality of life. Systematic reviews of RCTs have been published that found that conjunctival or limbal autograft is more effective than HAM graft in reducing the rate of pterygium recurrence. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

#### **Repair Following Mohs Micrographic Surgery**

For individuals who have undergone Mohs micrographic surgery for skin cancer on the face, head, neck, or dorsal hand who receive human amniotic/chorionic membrane, the evidence includes a nonrandomized, comparative study and no RCTs. Relevant outcomes are symptoms, morbid events, functional outcomes, and quality of life. A retrospective analysis using data from medical records compared a dehydrated human amniotic/chorionic membrane product (dHACM, Epifix) to repair using autologous surgery in 143 propensity-score matched pairs of patients requiring same-day reconstruction

after Mohs microsurgery for skin cancer on the head, face, or neck. A greater proportion of patients who received dHACM repair experienced zero complications (97.9% vs. 71.3%;  $p < .0001$ ; relative risk 13.97; 95% CI, 4.33 to 43.12). Placental allograft reconstructions developed less infection ( $p = .004$ ) and were less likely to experience poor scar cosmesis ( $p < .0001$ ). This study is limited by its retrospective observational design. Well-designed and conducted prospective studies are lacking. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

## Policy History

Date	Action
4/2024	Clarified coding information.
1/2024	Clarified coding information.
10/2023	Clarified coding information.
7/2023	Clarified coding information.
4/2023	Annual policy review. Description, summary, and references updated. Policy statements unchanged.
4/2023	Clarified coding information.
1/2023	Clarified coding information.
7/2022	Annual policy review. New indication and investigational statement added for treatment following Mohs microsurgery. Clarified coding information. Effective 7/1/2022.
4/2022	Clarified coding information.
1/2022	Clarified coding information.
10/2021	Clarified coding information.
7/2021	Annual policy review. Affinity added to medically necessary statement for the treatment of diabetic foot ulcers; edits made to investigational statement on human amniotic products. Clarified coding information. Effective 7/1/2021.
10/2020	Clarified coding information.
7/2020	Clarified coding information.
4/2020	Annual policy review. Description, summary and references updated. Policy statements unchanged.
1/2020	Clarified coding information.
10/2019	Clarified coding information.
7/2019	Annual policy review. New medically necessary and investigational indications described. EpiCord added to medically necessary statement for diabetic lower extremity ulcers. Clarified coding information. Effective 7/1/2019.
1/2019	Clarified coding information.
7/2018	Annual policy review. Investigational indications added. Clarified coding information. Effective 7/1/2018.
1/2018	Clarified coding information.
10/2017	Annual policy review. New medically necessary and investigational indications described. Ophthalmic products added and discontinued product names removed from Table 1. Clarified coding information. Effective 10/1/2017.
6/2017	Annual policy review. New medically necessary and investigational indications described. Clarified coding information. Effective 6/1/2017.
9/2015	New medical policy describing investigational indications. Effective 9/1/2015.

## Information Pertaining to All Blue Cross Blue Shield Medical Policies

Click on any of the following terms to access the relevant information:

[Medical Policy Terms of Use](#)

[Managed Care Guidelines](#)

[Indemnity/PPO Guidelines](#)

[Clinical Exception Process](#)

[Medical Technology Assessment Guidelines](#)



## References

1. Parolini O, Soncini M, Evangelista M, et al. Amniotic membrane and amniotic fluid-derived cells: potential tools for regenerative medicine?. *Regen Med*. Mar 2009; 4(2): 275-91. PMID 19317646
2. Koob TJ, Rennert R, Zabek N, et al. Biological properties of dehydrated human amnion/chorion composite graft: implications for chronic wound healing. *Int Wound J*. Oct 2013; 10(5): 493-500. PMID 23902526
3. Shimberg M, Wadsworth K. The use of amniotic-fluid concentrate in orthopaedic conditions. *J Bone Joint Surg*. 1938;20(l):167-177.
4. U.S. Food and Drug Administration. Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous Use Guidance for Industry and Food and Drug Administration Staff. 2017 <https://www.regulations.gov/document?D=FDA-2017-D-6146-0003> Accessed January 10, 2022
5. Food and Drug Administration. 510(k) Summary: ProKera™ Bio-Tissue Inc. (K032104). 2003; [https://www.accessdata.fda.gov/cdrh\\_docs/pdf3/K032104.pdf](https://www.accessdata.fda.gov/cdrh_docs/pdf3/K032104.pdf). Accessed January 10, 2022.
6. Serena TE, Yaakov R, Moore S, et al. A randomized controlled clinical trial of a hypothermically stored amniotic membrane for use in diabetic foot ulcers. *J Comp Eff Res*. Jan 2020; 9(1): 23-34. PMID 31691579
7. Ananian CE, Dhillon YS, Van Gils CC, et al. A multicenter, randomized, single-blind trial comparing the efficacy of viable cryopreserved placental membrane to human fibroblast-derived dermal substitute for the treatment of chronic diabetic foot ulcers. *Wound Repair Regen*. May 2018; 26(3): 274-283. PMID 30098272
8. Tettelbach W, Cazzell S, Sigal F, et al. A multicentre prospective randomised controlled comparative parallel study of dehydrated human umbilical cord (EpiCord) allograft for the treatment of diabetic foot ulcers. *Int Wound J*. Feb 2019; 16(1): 122-130. PMID 30246926
9. DiDomenico LA, Orgill DP, Galiano RD, et al. Use of an aseptically processed, dehydrated human amnion and chorion membrane improves likelihood and rate of healing in chronic diabetic foot ulcers: A prospective, randomised, multi-centre clinical trial in 80 patients. *Int Wound J*. Dec 2018; 15(6): 950-957. PMID 30019528
10. Snyder RJ, Shimozaki K, Tallis A, et al. A Prospective, Randomized, Multicenter, Controlled Evaluation of the Use of Dehydrated Amniotic Membrane Allograft Compared to Standard of Care for the Closure of Chronic Diabetic Foot Ulcer. *Wounds*. Mar 2016; 28(3): 70-7. PMID 26978860
11. Zelen CM, Gould L, Serena TE, et al. A prospective, randomised, controlled, multi-centre comparative effectiveness study of healing using dehydrated human amnion/chorion membrane allograft, bioengineered skin substitute or standard of care for treatment of chronic lower extremity diabetic ulcers. *Int Wound J*. Dec 2015; 12(6): 724-32. PMID 25424146
12. Zelen CM, Serena TE, Gould L, et al. Treatment of chronic diabetic lower extremity ulcers with advanced therapies: a prospective, randomised, controlled, multi-centre comparative study examining clinical efficacy and cost. *Int Wound J*. Apr 2016; 13(2): 272-82. PMID 26695998
13. Tettelbach W, Cazzell S, Reyzelman AM, et al. A confirmatory study on the efficacy of dehydrated human amnion/chorion membrane dHACM allograft in the management of diabetic foot ulcers: A prospective, multicentre, randomised, controlled study of 110 patients from 14 wound clinics. *Int Wound J*. Feb 2019; 16(1): 19-29. PMID 30136445
14. Lavery LA, Fulmer J, Shebetka KA, et al. The efficacy and safety of Grafix® for the treatment of chronic diabetic foot ulcers: results of a multi-centre, controlled, randomised, blinded, clinical trial. *Int Wound J*. Oct 2014; 11(5): 554-60. PMID 25048468
15. Smiell JM, Treadwell T, Hahn HD, et al. Real-world Experience With a Decellularized Dehydrated Human Amniotic Membrane Allograft. *Wounds*. Jun 2015; 27(6): 158-69. PMID 26061491
16. Frykberg RG, Gibbons GW, Walters JL, et al. A prospective, multicentre, open-label, single-arm clinical trial for treatment of chronic complex diabetic foot wounds with exposed tendon and/or bone: positive clinical outcomes of viable cryopreserved human placental membrane. *Int Wound J*. Jun 2017; 14(3): 569-577. PMID 27489115
17. Serena TE, Carter MJ, Le LT, et al. A multicenter, randomized, controlled clinical trial evaluating the use of dehydrated human amnion/chorion membrane allografts and multilayer compression therapy vs. multilayer compression therapy alone in the treatment of venous leg ulcers. *Wound Repair Regen*. 2014; 22(6): 688-93. PMID 25224019

18. Bianchi C, Cazzell S, Vayser D, et al. A multicentre randomised controlled trial evaluating the efficacy of dehydrated human amnion/chorion membrane (EpiFix®) allograft for the treatment of venous leg ulcers. *Int Wound J.* Feb 2018; 15(1): 114-122. PMID 29024419
19. Bianchi C, Tettelbach W, Istwan N, et al. Variations in study outcomes relative to intention-to-treat and per-protocol data analysis techniques in the evaluation of efficacy for treatment of venous leg ulcers with dehydrated human amnion/chorion membrane allograft. *Int Wound J.* Jun 2019; 16(3): 761-767. PMID 30864259
20. Vines JB, Aliprantis AO, Gomoll AH, et al. Cryopreserved Amniotic Suspension for the Treatment of Knee Osteoarthritis. *J Knee Surg.* Aug 2016; 29(6): 443-50. PMID 26683979
21. Tsikopoulos K, Vasiliadis HS, Mavridis D. Injection therapies for plantar fasciopathy ('plantar fasciitis'): a systematic review and network meta-analysis of 22 randomised controlled trials. *Br J Sports Med.* Nov 2016; 50(22): 1367-1375. PMID 27143138
22. Zelen CM, Poka A, Andrews J. Prospective, randomized, blinded, comparative study of injectable micronized dehydrated amniotic/chorionic membrane allograft for plantar fasciitis--a feasibility study. *Foot Ankle Int.* Oct 2013; 34(10): 1332-9. PMID 23945520
23. Cazzell S, Stewart J, Agnew PS, et al. Randomized Controlled Trial of Micronized Dehydrated Human Amnion/Chorion Membrane (dHACM) Injection Compared to Placebo for the Treatment of Plantar Fasciitis. *Foot Ankle Int.* Oct 2018; 39(10): 1151-1161. PMID 30058377
24. Suri K, Kosker M, Raber IM, et al. Sutureless amniotic membrane ProKera for ocular surface disorders: short-term results. *Eye Contact Lens.* Sep 2013; 39(5): 341-7. PMID 23945524
25. Liu J, Li L, Li X. Effectiveness of Cryopreserved Amniotic Membrane Transplantation in Corneal Ulceration: A Meta-Analysis. *Cornea.* Apr 2019; 38(4): 454-462. PMID 30702468
26. Yin HY, Cheng AMS, Tighe S, et al. Self-retained cryopreserved amniotic membrane for treating severe corneal ulcers: a comparative, retrospective control study. *Sci Rep.* Oct 12 2020; 10(1): 17008. PMID 33046729
27. Paris Fdos S, Gonçalves ED, Campos MS, et al. Amniotic membrane transplantation versus anterior stromal puncture in bullous keratopathy: a comparative study. *Br J Ophthalmol.* Aug 2013; 97(8): 980-4. PMID 23723410
28. Kheirkhah A, Casas V, Raju VK, et al. Sutureless amniotic membrane transplantation for partial limbal stem cell deficiency. *Am J Ophthalmol.* May 2008; 145(5): 787-94. PMID 18329626
29. Pachigolla G, Prasher P, Di Pasquale MA, et al. Evaluation of the role of ProKera in the management of ocular surface and orbital disorders. *Eye Contact Lens.* Jul 2009; 35(4): 172-5. PMID 19474753
30. Sharma N, Thenarasun SA, Kaur M, et al. Adjuvant Role of Amniotic Membrane Transplantation in Acute Ocular Stevens-Johnson Syndrome: A Randomized Control Trial. *Ophthalmology.* Mar 2016; 123(3): 484-91. PMID 26686968
31. Bouchard CS, John T. Amniotic membrane transplantation in the management of severe ocular surface disease: indications and outcomes. *Ocul Surf.* Jul 2004; 2(3): 201-11. PMID 17216092
32. John T, Tighe S, Sheha H, et al. Corneal Nerve Regeneration after Self-Retained Cryopreserved Amniotic Membrane in Dry Eye Disease. *J Ophthalmol.* 2017; 2017: 6404918. PMID 28894606
33. McDonald MB, Sheha H, Tighe S, et al. Treatment outcomes in the DRY Eye Amniotic Membrane (DREAM) study. *Clin Ophthalmol.* 2018; 12: 677-681. PMID 29670328
34. Tandon R, Gupta N, Kalaivani M, et al. Amniotic membrane transplantation as an adjunct to medical therapy in acute ocular burns. *Br J Ophthalmol.* Feb 2011; 95(2): 199-204. PMID 20675729
35. Eslani M, Baradaran-Rafii A, Cheung AY, et al. Amniotic Membrane Transplantation in Acute Severe Ocular Chemical Injury: A Randomized Clinical Trial. *Am J Ophthalmol.* Mar 2019; 199: 209-215. PMID 30419194
36. Tamhane A, Vajpayee RB, Biswas NR, et al. Evaluation of amniotic membrane transplantation as an adjunct to medical therapy as compared with medical therapy alone in acute ocular burns. *Ophthalmology.* Nov 2005; 112(11): 1963-9. PMID 16198422
37. Kaufman SC, Jacobs DS, Lee WB, et al. Options and adjuvants in surgery for pterygium: a report by the American Academy of Ophthalmology. *Ophthalmology.* Jan 2013; 120(1): 201-8. PMID 23062647
38. Clearfield E, Muthappan V, Wang X, et al. Conjunctival autograft for pterygium. *Cochrane Database Syst Rev.* Feb 11 2016; 2(2): CD011349. PMID 26867004
39. Toman J, Michael GM, Wisco OJ, et al. Mohs Defect Repair with Dehydrated Human Amnion/Chorion Membrane. *Facial Plast Surg Aesthet Med.* 2022; 24(1): 48-53. PMID 34714143

40. Hingorani A, LaMuraglia GM, Henke P, et al. The management of diabetic foot: A clinical practice guideline by the Society for Vascular Surgery in collaboration with the American Podiatric Medical Association and the Society for Vascular Medicine. *J Vasc Surg.* Feb 2016; 63(2 Suppl): 3S-21S. PMID 26804367
41. Lavery LA, Davis KE, Berriman SJ, et al. WHS guidelines update: Diabetic foot ulcer treatment guidelines. *Wound Repair Regen.* 2016; 24(1): 112-26. PMID 26663430